SUNLENCA sol inj 463.5 mg/1.5ml 2 flac 1.5 ml
7680683850012
CH-68385
J05AX31
08.03.0.
Reimbursement limitations:
SUNLENCA
Sunlenca est indiqué, en association avec un traitement antirétroviral de fond optimisé, pour le traitement …
1 / 3
google
Details
- Product number
- 6838501
- CPT
- -
- Packaging group
- 2
- Unit
- Durchstechflasche(n)
- Composition
- lenacapavirum 463.5 mg ut lenacapavirum natricum, macrogolum 300, aqua ad iniectabile, ad solutionem pro 1.5 ml corresp. natrium 10.99 mg.
Articles (1)
Sunlenca, Injektionslösung
Injektionslösung
2
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
463.5 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | WIZUS |
|
(N/A)
|
- | Substance | Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
10.99 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 20708.65
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/11/2024
Authorization holder
Gilead Sciences Switzerland Sàrl
6300 Zug
Authorization information
- Swissmedic authorization number
- 68385
- Drug name
- Sunlenca, Injektionslösung
- Galenic form
- LSINJ
- ATC Code
- J05AX31
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 07/07/2023
- Authorization expiration date
- 06/07/2028
- IT number
- 08.03.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- SUNLENCA sol inj 463.5 mg/1.5ml 2 flac 1.5 ml
- Description (DE)
- SUNLENCA Inj Lös 463.5 mg/1.5ml 2 Durchstf 1.5 ml
- Market launch
- 07/07/2023
- Narcotic (BTM)
- No